Lifeward Ltd. (LFWD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lifeward Ltd. (LFWD) Healthcare & Pipeline Overview

Lifeward Ltd. designs and commercializes medical devices, including exoskeletons and soft exo-suits, aimed at improving mobility and wellness for individuals with physical and neurological conditions. Operating globally, the company serves both institutions and individuals, positioning itself in the rehabilitation and assistive technology market.

What Is the Investment Thesis for LFWD?

Lifeward Ltd. operates in the growing medical device market, specifically targeting the rehabilitation and assistive technology sectors. With a market capitalization of $11.5M, the company's potential lies in the increasing demand for mobility solutions for individuals with physical and neurological conditions. Key value drivers include the expansion of their product line, particularly the ReStore and ReBoot soft exo-suits, and strategic partnerships to broaden market reach. While the company currently has a negative P/E ratio of -0.31 and a negative profit margin of -121.8%, successful commercialization and cost management could improve profitability. Ongoing catalysts include continued innovation in exoskeleton technology and favorable regulatory approvals for new products.

Based on FMP financials and quantitative analysis

LFWD Key Highlights

Market capitalization of $11.5M indicates the company's current valuation in the market.

• Gross margin of 37.5% reflects the profitability of Lifeward's products before operating expenses.
• Negative P/E ratio of -0.31 suggests the company is currently not profitable.
• Profit margin of -121.8% indicates significant operating losses.
• Beta of 0.14 suggests the stock is less volatile than the overall market.

Who Are LFWD's Competitors?

LFWD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LFWD's Key Strengths?

Innovative exoskeleton and soft exo-suit technology.

• Established presence in the rehabilitation market.
• Diverse product portfolio targeting various mobility impairments.
• Global distribution network.

What Are LFWD's Weaknesses?

Negative profitability and high operating losses.

• Limited market capitalization.
• Dependence on regulatory approvals.
• Competition from larger medical device companies.

What Could Drive LFWD Stock Higher?

Regulatory approvals for new products and indications.

• Expansion of sales and marketing efforts.
• Strategic partnerships with rehabilitation centers and hospitals.
• Technological advancements in exoskeleton technology.

What Are the Key Risks for LFWD?

Financial-distress signal — its Altman Z-Score of -13.97 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks and delays.
• Product liability claims.
• Competition from established medical device companies.
• Economic downturns affecting healthcare spending.
• Negative profitability and high operating losses.

What Are the Growth Opportunities for LFWD?

• Expansion of ReStore soft exo-suit: The market for stroke rehabilitation devices is substantial, with a growing need for effective therapies to improve motor function. Lifeward's ReStore soft exo-suit has the potential to capture a significant share of this market. Timeline: Ongoing.
• Commercialization of ReBoot personal exo-suit: The ReBoot personal soft exo-suit targets individuals post-stroke for home and community use, expanding Lifeward's reach beyond clinical settings. This device addresses the need for accessible and convenient rehabilitation solutions, tapping into a growing market for personal healthcare devices. The market for personal rehabilitation devices is expected to grow as technology advances and healthcare shifts towards more personalized care. Timeline: Ongoing.
• Strategic partnerships and distribution agreements: Collaborating with rehabilitation centers, hospitals, and distributors can significantly expand Lifeward's market reach and accelerate product adoption. Strategic alliances can provide access to new markets and customer segments, enhancing the company's competitive position. These partnerships can also facilitate the integration of Lifeward's products into existing rehabilitation programs and protocols. Timeline: Ongoing.
• Technological advancements in exoskeleton technology: Continuous innovation in exoskeleton technology, including improved battery life, lighter materials, and enhanced functionality, can drive product differentiation and market adoption. Investing in research and development to enhance the performance and usability of exoskeletons can attract a wider range of users and applications. Timeline: Ongoing.
• Expansion into new geographic markets: Expanding into new geographic markets, particularly in developing countries with growing healthcare infrastructure, can unlock significant growth opportunities for Lifeward. These markets often have unmet needs for rehabilitation and assistive technologies, providing a favorable environment for Lifeward's products. Timeline: Ongoing.

What Are LFWD's Competitive Advantages?

• Proprietary exoskeleton technology.
• Established brand recognition in the rehabilitation market.
• Distribution network with access to key customer segments.
• Intellectual property protection through patents.

What Does LFWD Do?

Lifeward Ltd., formerly known as ReWalk Robotics Ltd., was founded in 2001 and is headquartered in Yokneam Illit, Israel. The company focuses on developing and marketing technologies that aid mobility and wellness for individuals with physical and neurological conditions. Lifeward's product line includes ReWalk, a personal exoskeleton system designed to enable individuals with spinal cord injuries to stand and walk again, and ReStore, a soft exo-suit intended for stroke rehabilitation. They also offer the AlterG Anti-Gravity System, utilized in physical and neurological rehabilitation, as well as athletic training, and MyoCycle devices. The ReBoot, a personal soft exo-suit for post-stroke individuals, is also part of their offerings. Lifeward sells its products directly to institutions and individuals, and through third-party distributors, reaching markets in the United States, Europe, the Asia-Pacific region, and other international locations. The company rebranded to Lifeward Ltd. in September 2024, signaling a broader focus on overall wellness and mobility solutions.

What Products and Services Does LFWD Offer?

• Designs and develops exoskeleton systems for individuals with spinal cord injuries.
• Offers soft exo-suits for stroke rehabilitation.
• Provides anti-gravity systems for physical and neurological rehabilitation.
• Manufactures MyoCycle devices for therapeutic exercise.
• Commercializes ReBoot, a personal soft exo-suit for post-stroke individuals.
• Markets and sells products directly to institutions and individuals.
• Distributes products through third-party partners.

How Does LFWD Make Money?

• Direct sales to hospitals, rehabilitation centers, and clinics.
• Sales to individuals for personal use.
• Distribution agreements with third-party partners.
• Revenue from product maintenance and service contracts.

What Industry Does LFWD Operate In?

Lifeward Ltd. operates within the medical device industry, which is characterized by continuous innovation and increasing demand for advanced healthcare solutions. The market for rehabilitation and assistive technologies is growing, driven by an aging population, rising prevalence of neurological disorders, and increasing awareness of the benefits of mobility assistance. The company competes with other medical device manufacturers and technology companies in this space. The industry is subject to regulatory oversight, technological advancements, and evolving reimbursement policies.

Who Are LFWD's Key Customers?

• Hospitals and rehabilitation centers.
• Individuals with spinal cord injuries.
• Individuals recovering from stroke.
• Athletic training facilities.

Lifeward Ltd. (LFWD) Valuation Context

Valued at $11.5M, LFWD is classified as a micro-cap stock. Analyst price targets span from $10.00 to $10.00, with a consensus of $10.00. At the current price of $7.13, that implies approximately 40% upside potential. Relative to its peer group, LFWD's quantitative score of 20/100 is below the peer average of 42/100.

LFWD Revenue & Earnings Trend

In Q2 FY2026, LFWD generated $6.6M in top-line revenue, marking a sequential increase of 68.8%. The company recorded a net loss of $11.5M, with diluted EPS of $-4.12. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, LFWD averaged $-4.20 in diluted EPS.

Company Profile

Lifeward Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Yokneam Illit, IL. The company is led by CEO William Mark Grant. LFWD has traded publicly since 2014.

Key Financial Metrics

Return on assets is -88.1%, showing how much profit it generates from its asset base. A current ratio of 2.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -148.0%, the inverse of the P/E and a quick read on earnings relative to price.

Lifeward Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.97 places it in the distress zone, a signal of elevated financial risk.

Lifeward Ltd. has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 587.3% below estimates on average.

Over the past six months, Lifeward Ltd. insiders filed 11 SEC Form 4 transactions — 0 sales and 11 purchases. On net that is roughly 301K shares acquired (about $1.4M) — insiders putting money in tends to read as conviction.

LFWD Financials

LFWD Latest News

LFWD Analyst Consensus

LFWD MoonshotScore

Lifeward Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources